has been classified as an affected listed issuer under Practice Note 17 of the Main Market Listing Requirements of Bursa Malaysia.
Pharmaniaga said it will need to submit a regularisation plan to the Securities Commission Malaysia within 12 months if the plan will result in a significant change in the business direction or policy of the company. “As at the date of this announcement, the company is taking the necessary steps to address its PN17 status.
United Kingdom United Kingdom Latest News, United Kingdom United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: msianinsight - 🏆 8. / 63 Read more »